AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration Myriad Genetics.

This content was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent information service, is a scheduled system of the Kaiser Family members Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente. Â.. AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic contract with AbbVie, Inc. ‘We are excited to expand our collaboration with AbbVie, an emerging head in oncology, and believe their choice of Myriad as a commercial partner speaks to our unique ability to offer high quality, high value companion diagnostic examining on a global basis. In the scholarly study, researchers also looked at whether the association between fat distribution and cardiovascular disease risk was independent of body mass index , which assesses bodyweight relative to height, as well as other heart disease risk elements, such as high blood pressure and high cholesterol.Phil., M.D., Ph.D., lead author of the research and a study fellow in epidemiology and general public wellness at the University of Manchester in the United Kingdom.ADVENTRX’s second quarter net reduction decreases to $4.4 million ADVENTRX Pharmaceuticals, Inc. today reported economic results for the intervals ended June 30, 2011.S. Marketplace, should it be accepted on or around FDA’s PDUFA goal day of September 1, 2011, stated Brian M. Culley, Chief Executive Officer of ADVENTRX. In parallel, we will work to finalize the protocol for a phase 3 pediatric research of ANX-188, our first-in-class treatment for sickle cell crisis, for which FDA has granted orphan medication designation. We intend to initiate this scholarly study in 2012. Culley continued. Culley concluded.4 million, or $0.17 per share, in comparison to a net loss applicable to common stock of $5.0 million, or $0.39 per share, for the same period in 2010 2010.